Cargando…
Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024277/ https://www.ncbi.nlm.nih.gov/pubmed/36933100 http://dx.doi.org/10.1007/s10072-023-06754-4 |
| _version_ | 1784909066175250432 |
|---|---|
| author | Nakamagoe, Kiyotaka Tanaka, Mayuko Igari, Kota |
| author_facet | Nakamagoe, Kiyotaka Tanaka, Mayuko Igari, Kota |
| author_sort | Nakamagoe, Kiyotaka |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10024277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100242772023-03-21 Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration Nakamagoe, Kiyotaka Tanaka, Mayuko Igari, Kota Neurol Sci Letter to the Editor Springer International Publishing 2023-03-18 /pmc/articles/PMC10024277/ /pubmed/36933100 http://dx.doi.org/10.1007/s10072-023-06754-4 Text en © Fondazione Società Italiana di Neurologia 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Nakamagoe, Kiyotaka Tanaka, Mayuko Igari, Kota Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title | Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title_full | Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title_fullStr | Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title_full_unstemmed | Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title_short | Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| title_sort | cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024277/ https://www.ncbi.nlm.nih.gov/pubmed/36933100 http://dx.doi.org/10.1007/s10072-023-06754-4 |
| work_keys_str_mv | AT nakamagoekiyotaka casesofaquaporin4positiveneuromyelitisopticaspectrumdisorderwithsuccessfultaperingofprednisolonetolessthan3mgdayaftersatralizumabadministration AT tanakamayuko casesofaquaporin4positiveneuromyelitisopticaspectrumdisorderwithsuccessfultaperingofprednisolonetolessthan3mgdayaftersatralizumabadministration AT igarikota casesofaquaporin4positiveneuromyelitisopticaspectrumdisorderwithsuccessfultaperingofprednisolonetolessthan3mgdayaftersatralizumabadministration |